(CercleFinance.com) – PostNL sells nearly 5% to Amsterdam, penalized by an analysis by UBS which today downgraded its advice on the stock from ‘buy’ to ‘neutral’, while sharply reducing its target for course, reduced from 118 to 103 euros.
In a study published in the morning, analysts at the Swiss bank said they expect the laboratory’s action to “pause” following the recent upward revision of its objectives for 2022.
After the two clinical failures of amcenestrant in breast cancer and tolebrutinib in multiple sclerosis, UBS says it doesn’t see many catalysts likely to drive value by the end of the year.
The Swiss establishment also mentions the prospect of the loss of the patent on Aubagio, next year, and R&D costs which continue to climb.
Finally, UBS fears that the litigation surrounding the drug against heartburn Zantac, suspected of containing a carcinogenic ingredient, will prove problematic at the time of its legal treatment, scheduled for early 2023 in the United States.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
